She was diagnosed with a bladder condition, but in reality, she had two tumors: one the size of a football and the other the ...

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

Researchers take a closer look at how animal species, large and small, evolved to fight cancer and what it means for humans ...

Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

Data at ESMO 2025 bolstered the case that blood tests could help doctors sort which patients need additional therapy, and who ...

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical ...

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.

Brigadeer Gareth Collett protected countless lives in his work, and he is now aiming to save hundreds more with research into ...

Adjuvant nivolumab (Opdivo) continued to show benefits in disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgery, ...